Ekso Bionics (NASDAQ:EKSO) Posts Quarterly Earnings Results, Misses Estimates By $1.48 EPS

Ekso Bionics (NASDAQ:EKSO) issued its quarterly earnings results on Monday. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($1.48), FiscalAI reports. Ekso Bionics had a negative return on equity of 90.71% and a negative net margin of 70.74%.The firm had revenue of $3.14 million during the quarter, compared to analyst estimates of $5.03 million.

Ekso Bionics Trading Down 4.8%

Shares of EKSO stock traded down $0.54 on Monday, hitting $10.64. 105,868 shares of the stock traded hands, compared to its average volume of 285,826. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.09 and a current ratio of 1.66. Ekso Bionics has a twelve month low of $2.73 and a twelve month high of $13.27. The firm’s 50-day moving average price is $8.30 and its two-hundred day moving average price is $5.78. The stock has a market capitalization of $27.88 million, a PE ratio of -1.87 and a beta of 0.80.

Analysts Set New Price Targets

A number of brokerages have weighed in on EKSO. Weiss Ratings restated a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. HC Wainwright downgraded shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 31st. Finally, Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.50.

Insider Buying and Selling

In other news, major shareholder Daniel Asher bought 15,540 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were bought at an average cost of $12.30 per share, for a total transaction of $191,142.00. Following the acquisition, the insider directly owned 270,432 shares of the company’s stock, valued at $3,326,313.60. This trade represents a 6.10% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 6.10% of the stock is owned by company insiders.

Institutional Trading of Ekso Bionics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new stake in shares of Ekso Bionics during the 3rd quarter valued at approximately $198,000. Geode Capital Management LLC raised its position in Ekso Bionics by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after purchasing an additional 10,281 shares during the period. Shay Capital LLC purchased a new stake in Ekso Bionics in the third quarter valued at $67,000. Finally, Virtu Financial LLC acquired a new position in shares of Ekso Bionics in the 3rd quarter valued at $57,000. Institutional investors and hedge funds own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.